Celldex Therapeutics was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. A critical component of this strategy includes combining therapeutic approaches to leverage the power of the immune system’s response. We accomplish this by not only fully maximizing our own pipeline but also by identifying promising external technologies that will complement it. Likewise, when appropriate, we consider entering into partnerships for Celldex-owned programs that will enhance our mutual ability to advance novel science and accelerate the development of truly life-changing therapies for patients. For more information on partnering opportunities, please email firstname.lastname@example.org.
Current collaborations include:
Amgen Inc. – Celldex acquired exclusive rights from Amgen to develop and commercialize two immune-stimulatory molecules known as FMS-like tyrosine kinase 3 ligand or Flt3L (now referred to as CDX-301) and CD40 ligand (CD40L).
Medarex (now Bristol-Myers Squibb) – In 2005, Celldex was spun out of the New Jersey based biopharmaceutical company Medarex (acquired by the Bristol-Myers Squibb Company) and, in connection with this transaction, we retain the rights to obtain exclusive commercial licenses to proprietary monoclonal antibodies raised against certain antigens utilizing the Medarex UltiMAb technology platform.
Rockefeller University (Rockefeller) – Celldex has licensed intellectual property from Rockefeller to target the DEC-205 family of mannose receptors in human dendritic cells, leveraging discoveries from the laboratories of the late Nobel Laureate Professor Ralph Steinman and Professor Michel Nussenzweig. Celldex is also collaborating with Rockefeller to develop CDX-2401, a novel vaccine against HIV, the virus known to cause AIDS. This project is supported through a grant from the Bill & Melinda Gates Foundation and utilizes human antibodies to DEC-205 receptors to selectively generate robust immune responses against specifically selected HIV antigens.
University of Southampton, UK – Celldex has a license agreement with Southampton to develop human antibodies towards CD27, a potentially significant target for immunotherapy of various cancers.
MERCK – Celldex has amended the ongoing Phase 1 study of CDX-1140 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy under a clinical trial collaboration with Merck (know as MSD outside of the U.S. and Canada). The cohort is designed to characterize the safety, pharmacodynamics and activity of CDX-1140 in combination with pembrolizumab in patients refractory to PD1/PDL1 treatment. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsuduary of Merck & Co., Inc., Kenilworth, NJ USA.